Bienvenidos a Madrid para #ESMO26
🎥 Nueva Educational Capsule | @GuardConsortium
🇪🇸 TALAPRO-3: ¿Un nuevo paso para los PARP inhibitors en prostate cancer hormonosensible?

Dr. Joaquín Mateo (@quimmateo) from @VHIO in Barcelona breaks down the TALAPRO-3 trial, presented at ASCO 2026 and published in the New England Journal of Medicine, alongside @AzadOncology, @neerajaiims and colleagues.

🧬 What did TALAPRO-3 show?

This phase 3 trial evaluated talazoparib + enzalutamide versus placebo + enzalutamide in patients with HRR-altered metastatic hormone-sensitive prostate cancer (mHSPC).

🔹 599 patients enrolled across both treatment arms.

🔹 Radiographic progression-free survival (rPFS) at 3 years: 77% vs. 56% (HR 0.48; 95% CI 0.36–0.65; p<0.001).

🔹 Overall survival (OS): 78% vs. 72% at 3 years in the interim analysis (HR 0.77; 95% CI 0.56–1.04). OS data remain immature.

🔹 Safety matters: Grade ≥3 anemia occurred in 51% of patients receiving talazoparib.

💡 La gran pregunta: ¿Estamos ante un cambio en el papel de los PARP inhibitors, moving them earlier into the hormone-sensitive setting?

Watch Dr. Mateo’s analysis and join the conversation. 👇

🔗 https://nejm.org/doi/full/10.1056/NEJMoa2604126?referrer=https%3A%2F%2Fwww.google.com%2F

#GuardConsortium #TALAPRO3 #ProstateCancer #ASCO2026

GU Oncology colleagues: @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @Ecastromarcos @abraocantoMD @AlvarezMa89031 @OncBrothers @Helena_de_Palma @DrIacovelli @mjuanfi81

OncoALert faculty: @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @amerseburger @sonpavde @scserendipity1 @Silke_Gillessen @EfstathiouEleni @BraunMDPhD @nataliagandur @brian_rini @AOmlin @realbowtiedoc @AmandaNizamMD @AndreaNecchi @scocmem